Maxillo-facial

GDF-5 has been demonstrated to induce bone, cartilage and tendon/ ligament formation. Various pre-clinical studies have supported the use of rhGDF-5 for clinical applications including bone induction and soft tissue growth.

The product line MD05 has been developed as a novel regenerative bone substitute material related to dentistry for dental implantology and surgical treatment of periodontal disease. MD05 consists of two components: the recombinant human growth and differentiation factor-5 (rhGDF-5) and the inorganic carrier beta-tricalcium phosphate (ß-TCP). GDF-5, a naturally occurring human protein that acts by promoting the growth of bone combining osteoconductive and osteoinductive properties. ß-TCP, a well accepted biomaterial for bone augmentation in dentistry and orthopaedic surgery is a synthetic biomaterial that acts as a scaffold and space-maintainer for new bone ingrowth. These two components are combined enabling a highly stable and homogeneous association between them while maintaining the structural and biologic integrity of the growth factor.

MD05-P is a product for periodontal disease. The project has entered clinical phase III for the treatment of severe periodontitis.

MD05-I is a bone augmentation product for dental implantology. A clinical phase II trial in which MD05-I was examined for the treatment for dental implantology has successfully been completed.

We are now looking for an opportunity to license out this products for further clinical development and commercialization.Please contact us for additional information.